JP2022500392A5 - - Google Patents

Info

Publication number
JP2022500392A5
JP2022500392A5 JP2021513407A JP2021513407A JP2022500392A5 JP 2022500392 A5 JP2022500392 A5 JP 2022500392A5 JP 2021513407 A JP2021513407 A JP 2021513407A JP 2021513407 A JP2021513407 A JP 2021513407A JP 2022500392 A5 JP2022500392 A5 JP 2022500392A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500392A (ja
JP7554739B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051603 external-priority patent/WO2020061113A1/en
Publication of JP2022500392A publication Critical patent/JP2022500392A/ja
Publication of JP2022500392A5 publication Critical patent/JP2022500392A5/ja
Application granted granted Critical
Publication of JP7554739B2 publication Critical patent/JP7554739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513407A 2018-09-18 2019-09-17 ファルネソイドx受容体アゴニストおよびその使用 Active JP7554739B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733006P 2018-09-18 2018-09-18
US201862733004P 2018-09-18 2018-09-18
US62/733,004 2018-09-18
US62/733,006 2018-09-18
US201962881560P 2019-08-01 2019-08-01
US62/881,560 2019-08-01
PCT/US2019/051603 WO2020061113A1 (en) 2018-09-18 2019-09-17 Farnesoid x receptor agonists and uses thereof

Publications (3)

Publication Number Publication Date
JP2022500392A JP2022500392A (ja) 2022-01-04
JP2022500392A5 true JP2022500392A5 (enExample) 2022-09-27
JP7554739B2 JP7554739B2 (ja) 2024-09-20

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513407A Active JP7554739B2 (ja) 2018-09-18 2019-09-17 ファルネソイドx受容体アゴニストおよびその使用

Country Status (27)

Country Link
US (4) US11084817B2 (enExample)
EP (2) EP4596543A3 (enExample)
JP (1) JP7554739B2 (enExample)
KR (2) KR102810978B1 (enExample)
CN (1) CN113056271B (enExample)
AU (2) AU2019344903B2 (enExample)
BR (1) BR112021004919A2 (enExample)
CA (1) CA3112411A1 (enExample)
CL (1) CL2021000632A1 (enExample)
DK (1) DK3852748T3 (enExample)
ES (1) ES3051007T3 (enExample)
FI (1) FI3852748T3 (enExample)
HR (1) HRP20251321T1 (enExample)
IL (1) IL281475B2 (enExample)
LT (1) LT3852748T (enExample)
MA (1) MA53665B1 (enExample)
MD (1) MD3852748T2 (enExample)
MX (1) MX2021003110A (enExample)
PH (1) PH12021550605A1 (enExample)
PL (1) PL3852748T3 (enExample)
PT (1) PT3852748T (enExample)
RS (1) RS67371B1 (enExample)
SG (1) SG11202102651SA (enExample)
SI (1) SI3852748T1 (enExample)
SM (1) SMT202600076T1 (enExample)
TW (1) TWI833805B (enExample)
WO (1) WO2020061113A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3609888T (lt) * 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2021188695A1 (en) * 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
CN120732854A (zh) * 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
IL296532A (en) * 2020-03-18 2022-11-01 Metacrine Inc Crystal forms of farnesoid x receptor agonist
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
WO2000071518A2 (en) 1999-05-25 2000-11-30 Sepracor, Inc. Heterocyclic analgesic compounds and their use
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
AU2001216218A1 (en) 2000-05-25 2001-12-11 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
US20040102431A1 (en) 2000-09-25 2004-05-27 Christoph Boss Substituted amino-aza-cycloalkanes useful against malaria
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004026823A1 (en) 2002-09-20 2004-04-01 Pfizer Products Inc. Amide and sulfonamide ligands for the estrogen receptor
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
AU2003298654A1 (en) 2002-11-15 2004-06-15 The Salk Institute For Biological Studies Structure of the farnesoid x receptor ligand binding domain and methods of use therefor
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
PL1648874T3 (pl) 2003-07-30 2012-04-30 Xenon Pharmaceuticals Inc Pochodne piperazyny i ich zastosowanie jako środków leczniczych
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005058822A1 (en) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Substituted amino-cycloalkanes
JP2007530582A (ja) 2004-03-26 2007-11-01 ライジェル ファーマシューティカルズ, インコーポレイテッド 代謝可能部分を含む複素環抗ウイルス化合物およびその使用
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
MX2008012404A (es) 2006-03-28 2008-10-09 Novartis Ag Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2010001869A1 (ja) 2008-06-30 2010-01-07 武田薬品工業株式会社 4置換ベンゼン化合物およびその用途
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
JP2012532914A (ja) 2009-07-15 2012-12-20 メルク セローノ ソシエテ アノニム テトラゾール誘導体
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
SI2688403T1 (sl) 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9492763B2 (en) 2011-07-13 2016-11-15 M. Technique Co., Ltd. Method for producing microparticles having controlled crystallite diameter
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
EP3116878A4 (en) 2014-03-13 2018-02-14 Salk Institute for Biological Studies Fxr agonists and methods for making and using
WO2016116054A1 (en) 2015-01-22 2016-07-28 Xiamen University Modulators of farnesoid x receptor and methods for the use thereof
JP2018510866A (ja) 2015-03-13 2018-04-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腸受容体を活性化させるための、ファルネソイドx受容体アゴニストでの、成体の潜在性自己免疫性糖尿病の治療
WO2017018751A1 (ko) 2015-07-24 2017-02-02 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
JP2018536016A (ja) * 2015-09-16 2018-12-06 メタクリン,インク. ファルネソイドx受容体アゴニストとその使用
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
WO2017049173A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350158A4 (en) 2015-09-16 2019-05-08 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
WO2017170182A1 (ja) 2016-03-31 2017-10-05 株式会社Adeka 感光性組成物及び新規化合物
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170167A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
LT3609888T (lt) 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (ko) 2018-09-17 2020-03-26 엘지전자 주식회사 5g 이동통신에서 pdu 세션을 핸들링하는 방법 및 무선 기기
MA53671A (fr) 2018-09-18 2021-07-28 Metacrine Inc Formes cristallines d'un agoniste du récepteur farnésoïde x
EA202190661A1 (ru) 2018-09-18 2021-08-13 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора для лечения заболевания
WO2020061118A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
WO2020061116A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20220054469A1 (en) 2018-09-18 2022-02-24 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP2022500393A (ja) 2018-09-18 2022-01-04 メタクリン,インク. ファルネソイドx受容体アゴニストおよびその使用
IL296532A (en) 2020-03-18 2022-11-01 Metacrine Inc Crystal forms of farnesoid x receptor agonist
CN120732854A (zh) 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist

Similar Documents

Publication Publication Date Title
JP2022500392A5 (enExample)
JP2020514333A5 (enExample)
JP2014524472A5 (enExample)
ES2546063T3 (es) Agentes de enlace a amiloides
JP2009084270A5 (enExample)
TWI591047B (zh) 巨大戟萜醇-3-醯化物iii及巨大戟萜醇-3-胺基甲酸酯化物
JP2024520481A5 (enExample)
JP2021534124A5 (enExample)
JP2022533069A5 (enExample)
JP2010512342A5 (enExample)
JP2019518071A (ja) Nlrp活性に関連する状態を処置するための化合物および組成物
JP2011523412A5 (enExample)
JP2021527638A5 (enExample)
JP2018188478A (ja) 肝疾患を処置する方法
JP2011016849A5 (enExample)
RU2016137832A (ru) Соединения для лечения опосредованных комплементом нарушений
JP2014511891A5 (enExample)
RU2015105262A (ru) Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
JP2017512186A5 (enExample)
JP2016530209A5 (enExample)
JP2006515838A5 (enExample)
JP2020529994A5 (enExample)
JP2010501584A5 (enExample)
JP2007504284A5 (enExample)
JP2013508279A5 (enExample)